INTRODUCTION Approved in 2011, vemurafenib is a selective serine/threonine kinase inhibitor directed against the V600E mutation in the BRAF gene. This drug is often used in dermatology as a targeted therapy for metastatic or unresectable melanomas, for which about 50% have this mutation. Other tumors possessing the V600E mutation are targets for this therapy. The commonly reported adverse effec...